A Multicenter Phase I/II Study of Cabozantinib Alone or in Combination with Panitumumab in Patients with MET-amplified metastatic colorectal cancer
Latest Information Update: 07 Jan 2022
At a glance
- Drugs Cabozantinib (Primary) ; Panitumumab (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms METBEIGE Study
- 23 Dec 2021 New trial record